logo-loader

VolitionRx boosts cash reserves in 1Q

Published: 16:33 08 May 2019 EDT

lab tech
Volition's NuQ diagnostic blood tests pinpoints irregular levels of nucleosomes in the blood, which indicate cancer

VolitionRx Limited (NYSE AMERICAN:VNRX) on Wednesday announced that it ended its first quarter with $16.2 million in cash and cash equivalents, growing its cash reserves. 

The life-sciences company noted that it had $13.4 million in cash and cash equivalents at the end of 2018. In addition, VolitionRx said it continues to manage cash carefully with a cash burn of $3.9 million in the first quarter, which ended March 31.

WATCH: VolitionRx well positioned as it enters Q2 after strengthening balance sheet

"During the first quarter 2019, we further strengthened our balance sheet with existing investors exercising $6.7 million in aggregate amount of outstanding warrants to purchase shares of our common stock,” said CEO Cameron Reynolds.

He added that “subsequent to the ending of the quarter, a further $5 million in warrants were exercised for cash, making a total of $11.7 million in warrants exercised this year."

The company has designed routine Nu.Q blood-based diagnostic tests to screen for colorectal and prostate cancers that reduce the need for more invasive colonoscopies and biopsies.

VolitionRx’s stock rose 2.15% Wednesday to close at $3.33 a share.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Novo Resources sees substantial upside potential at Nunyerry

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO) co-chair and acting CEO Mike Spreadborough joins Jonathan Jackson in the Proactive studio to discuss promising gold outcomes from recent reanalysis of drill intercepts in a 2023 program at Nunyerry North in Western Australia. Using advanced...

10 hours, 35 minutes ago